Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06341296
Other study ID # CSPC-DEY-CRC-K07
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date December 2026

Study information

Verified date May 2024
Source West China Hospital
Contact Meng Qiu, MD
Phone 028-85423203
Email qiumeng33@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the objective response rate, disease control rate, progression-free survival, overall survival, surgical conversion rate and safety of irinotecan liposome combined with 5-FU/LV+ bevacizumab regimen in first-line treatment of advanced metastatic colorectal cancer patients.


Description:

This is a Phase II clinical study to evaluate the efficacy and safety of the combination regimen of irinotecan liposome injection in the first-line treatment of metastatic colorectal cancer. Patients will receive liposomal injections of irinotecan 70mg/m^2 d1, bevacizumab 5mg/kg d1, LV 400mg/m^2 d1, 5-FU 400mg/m^2, then 2400mg/m^2, continuous intravenous infusion for 46-48h, d1-2. 86 eligible patients will be enrolled.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 86
Est. completion date December 2026
Est. primary completion date April 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - 18~85 years old. - Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma. - RAS/BRAF v600e mutant or right half colon cancer is known. - pMMR/MSS is known. - The unresectable stage of metastatic disease has not received any systemic antitumor therapy. - For subjects previously receiving neoadjuvant or adjuvant therapy, the date of first discovery of disease progression must be at least 6 months removed from the date of last administration of neoadjuvant or adjuvant therapy. - ECOG 0~1, patients =75 years old need an ECOG score of 0 - The presence of at least 1 measurable lesion that can be evaluated according to the RECIST v1.1 criteria. - Normal bone marrow and organ function: ? Neutrophils (ANC) =1.5×10^9/L, platelets (PLT) =100×10^9/L, hemoglobin (Hb) =80g/L, albumin (ALB) =30 g/L, white blood cells (WBC) =3.0×10^9/L, and no bleeding tendency; ? AST, ALT and alkaline phosphatase (ALP) were all =2.5× upper limit of normal range (ULN), and =5×ULN when liver metastases occurred; The total bilirubin level doesn't exceed the upper limit of the agency's normal range; Serum creatinine (Cr) =1.5×ULN or creatinine clearance =40 ml/min (calculated according to Cockroft-Gault) - Understand the situation of this study, patients and/or legal representatives voluntarily agree to participate in this study and sign informed consent form. Exclusion Criteria: - Known or suspected central nervous system metastasis. - Received irinotecan/irinotecan liposomes/bevacizumab before enrollment. - Had undergone surgery and other oncologic treatments within the first 4 weeks of enrollment. - Previous treatment-related toxicity didn't return to NCI-CTCAE v5.0 I or below(except hair loss and peripheral neuropathy). - The use of CYP3A, CYP2C8, and UGT1A1 inhibitors or inducers couldn't be discontinued or were not discontinued within 2 weeks prior to enrollment. - Severe gastrointestinal dysfunction, gastrointestinal perforation, intraperitoneal abscess, and fistula. - Intestinal obstruction, signs and symptoms of intestinal obstruction, or the stent has been previously implanted and the stent has not been removed before the screening period. - Interstitial lung disease. - Tendency of arterial embolism and massive bleeding within 6 months before enrollment (except surgical bleeding). - Patients with fluid accumulation that couldn't reach a stable state but small amount of ascites on imaging without clinical symptoms could be enrolled. - Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, heart disease, active bleeding, active viral infection, etc. - Have had other malignancies within the past 5 years or currently, except cured cervical carcinoma in situ, uterine carcinoma in situ, and non-melanoma skin cancer. - Patients of childbearing age who refuse to take contraceptives, women who are pregnant or breastfeeding. - The researchers didn't consider it appropriate to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Irinotecan Liposome
70 mg/m^2 , d1, 14 days per cycle, 8 cycles.
5-FU
5-FU 400mg/m^2, then 2400mg/m^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
LV
400mg/m^2, d1, 14 days per cycle, 8 cycles.
Bevacizumab
5mg/kg, d1, 14 days per cycle, 8 cycles.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
West China Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate To investigate antitumor efficacy of study. From initial medication to the date of first documented progression or end of medication or completed 8 cycles treatment, whichever came first . Assessed up to 4 months
Secondary Disease control rate To investigate antitumor efficacy of study. From initial medication to the date of first documented progression or end of medication or completed 8 cycles treatment, whichever came first. Assessed up to 4 months
Secondary Progression free survival To investigate antitumor efficacy of study. From initial medication to the date of first documented progression or end of medication, whichever came first. Assessed up to 30 months.
Secondary Overall survival To investigate antitumor efficacy of study. From initial medication to the date of death from any cause. Assessed up to 30 months.
Secondary Percentage of patients undergoing surgery. To assess surgical conversion rates in patients who could be surgically resected. From the first dose to completed 8 cycles treatment. Assessed up to 5 months.
Secondary R0 resection To assess surgical conversion rates in patients who could be surgically resected. From the first dose to the surgery. Assessed up to 6 months.
Secondary Incidence of adverse events and severity of adverse events as assessed by CTCAE 5.0 To assess the incidence and severity of adverse events in combination regimens. From the first dose to completed 8 cycles treatment. Assessed up to 5 months.
See also
  Status Clinical Trial Phase
Completed NCT01228734 - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. Phase 1/Phase 2
Withdrawn NCT05412706 - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy Phase 2
Withdrawn NCT04430985 - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer Phase 2
Withdrawn NCT03182894 - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05725200 - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer Phase 1
Completed NCT04866290 - HepaSphere™ Microspheres Prospective Registry
Not yet recruiting NCT06425133 - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers Phase 2
Not yet recruiting NCT05531045 - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02906059 - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02575378 - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Phase 4
Withdrawn NCT02535988 - Abscopal Effect for Metastatic Colorectal Cancer Phase 2
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT02077868 - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3
Completed NCT02414009 - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Phase 2
Active, not recruiting NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Phase 2
Withdrawn NCT01915472 - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2